摘要:OBJECTIVE: To probe into the efficacy of Calcium dobesilate capsule combined with compound Xueshuantong capsule in treatment of vitreous hemorrhage .METHODS:98 patients with vitreous hemorrhage admitted into Yidu the First People's Hospital from Mar.2015 to Apr.2016 were selected and divided into observation group and control group via random number table , with 49 cases in each .The control group was treated with Calcium dobesilate capsule , while the observation group was given Calcium dobesilate capsule combined with compound Xueshuantong capsule .Clinical efficacy , areas of hemorrhage spot , thicknesses of macular lutea , gray values of vision, volumes of hemangioma, level of serum vascular endothelial growth factor (VEGF), level of serum insulin-like growth factor 1 ( IGF-1 ) and incidences of adverse drug reactions of two groups were observed and compared . RESULTS:The total effective rate of observation group was 91.8%(45/49), which was significantly higher than that of the control group (77.6%, 38/49), with statistically significant difference (P<0.05);after treatment, the areas of hemorrhage spot , thicknesses of macular lutea , gray values of vision and volumes of hemangioma of both groups had been significantly improved , and those of the observation group were significantly better than the control group , with statistically significant differences ( P<0.05 ); after treatment , levels of serum VEGF and IGF-1 of both groups had been significantly decreased , and those of the observation group were significantly lower than the control group , with statistically significant differences ( P<0.05);the incidence of adverse drug reactions of observation group was 8.0%(4/49), which was significantly lower than that of the control group (30.6%, 15/49), with statistically significant difference ( P <0.05 ).CONCLUSIONS: The efficacy of Calcium dobesilate capsule combined with compound Xueshuantong capsule in treatment of vitreous hemorrhage is remarkable , which can significantly improve clinical syndromes, promote vision, reduce levels of serum VEGF and IGF-1, with low incidence of adverse drug reactions .%目的:探讨羟苯磺酸钙胶囊联合复方血栓通胶囊治疗玻璃体积血的疗效.方法:选取2015年3月—2016年4月宜都市第一人民医院收治的玻璃体积血患者98例,以随机数字表法分为观察组和对照组,每组49例.对照组患者给予羟苯磺酸钙胶囊,观察组患者在对照组基础上加用复方血栓通胶囊.对比观察两组患者的临床疗效、出血斑面积、黄斑厚度、视野灰度值、血管瘤体积、血清血管内皮生长因子(vascular endothelial growth factor,VEGF)、胰岛素样生长因子1(insulin-like growth factor 1,IGF-1)水平及不良反应发生情况.结果:观察组患者的总有效率为91.8%(45/49),明显高于对照组的77.6%(38/49),差异有统计学意义(P<0.05);治疗后,两组患者出血斑面积、黄斑厚度、视野灰度值及血管瘤体积均较治疗前明显改善,且观察组患者明显优于对照组,差异均有统计学意义(P<0.05);治疗后,两组患者血清VEGF、IGF-1水平均较治疗前明显降低,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05);观察组患者不良反应发生率为8.0%(4/49),明显低于对照组的30.6%(15/49),差异有统计学意义(P<0.05).结论:羟苯磺酸钙胶囊联合复方血栓通胶囊治疗玻璃体积血的疗效显著,可有效改善患者临床症状,提高视力,降低血清VEGF和IGF-1水平,且不良反应少.